Month: January 2023

Figure 1: Property map showing the location of the Tarabala prospectFigure 2: Summary drilling results on the Tarabala Trend and the location of the planned RC drill holesToronto, Jan. 05, 2023 (GLOBE NEWSWIRE) — Compass Gold Corp. (TSX-V: CVB) (Compass or the Company) announced today that it has completed its previously announced private placement financing and is preparing to launch a follow-up drilling program to test previously identified mineralized sections at depth along the Tarabala Trend on its Sikasso Property in Southern Mali (Figure 1). HighlightsClosed previously announced private placement financing for gross proceeds of $700,000 Field teams to be mobilized to prepare drill pads for follow-up deeper drilling at the Tarabala prospect, including where metallic screen fire assaying reported 7 m at 14.13 g/t...

SAN JUAN, Puerto Rico, Jan. 05, 2023 (GLOBE NEWSWIRE) — Red Cat Holdings, Inc. (Nasdaq: RCAT) (“Red Cat” or the “Company”), a military technology company that integrates robotic hardware and software to provide critical situational awareness and actionable intelligence to on-the-ground warfighters and battlefield commanders, today announced an important new partnership. Opening day of the Consumer Electronics Show (CES) in Las Vegas, Nevada, brought the announcement that Teal Drones, a Red Cat subsidiary, has partnered with leading Canadian optical products manufacturer Immervision, whose latest navigation camera module is used for surveillance and unmanned systems. Immervision will provide Teal’s flagship drone with exceptional low-light capabilities – capabilities that Immervision demonstrated at CES. Teal...

BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced a clinical supply agreement with Regeneron for its anti-PD1 therapy Libtayo® (cemiplimab). The supply agreement supports the evaluation of SNS-101, a conditionally active VISTA-blocking antibody, in combination with Libtayo® in a Phase 1/2 trial in solid tumors. Sensei is on track to submit an Investigational New Drug application for SNS-101 in or before April 2023 and the trial is expected to commence in 2023 pending regulatory clearance. “We are excited for the opportunity to work with Regeneron on our planned clinical trial of SNS-101, which has demonstrated strong anti-tumor activity in combination with PD-1 inhibition...

BEIJING, Jan. 05, 2023 (GLOBE NEWSWIRE) — ZW Data Action Technologies, Inc. (Nasdaq: CNET) (“ZW Data” or the “Company”), an integrated online advertising, precision marketing, data analytics, and other value-added services company, today announced a strategic cooperation with Superwin Technology Pte. Ltd. (“Superwin”). Both parties intend to jointly establish a Web3.0 application service platform (“Platform”), through which the Company expects to provide basic computing power and blockchain services for Web3.0 application suppliers. The Company expects to bring commercial value to enterprise users and achieve efficiency in utilizing computing power resources, integrated management, and flexible scheduling, through the Platform. Superwin, headquartered in Singapore, operates data center, computing and mining...

Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG) Trial size to be adapted upon interim analysis with planned total patient number between approximately 50 and 100 patients FDA review of application for emergency use authorization (EUA) of vilobelimab for the treatment of critically ill COVID-19 patients ongoing InflaRx’s management team to host investor and business meetings during JPM Week, January 9 – 12, 2023 in San Francisco, CaliforniaJENA, Germany, Jan. 05, 2023 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced details related to the design of its planned Phase III study with vilobelimab in ulcerative PG, a rare neutrophilic...

CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced that Priya Singhal, M.D., M.P.H., currently Head of Global Safety and Regulatory Sciences and Interim Head of Research & Development (R&D), has been promoted to Executive Vice President, Head of Development, following a decision to separate Research and Development into two distinct functions that will both report directly to the CEO. In addition, Biogen has initiated a search for a new Executive Vice President, Head of Research; Dr. Singhal will serve as interim head of Research until a new leader is named. “Throughout her tenure at Biogen, Priya has demonstrated excellent leadership and judgement. In this new role, Priya will focus on delivering on our development programs while working closely with a new dedicated head of Research...

Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023 Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into Phase 1 clinical trials in 2023 Strong financial position; cash runway into Q4 2024 WARMINSTER, Pa., Jan. 05, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced its 2023 corporate objectives and provided a financial update. William Collier, President and CEO of Arbutus Biopharma, stated, “Building upon our accomplishments in 2022, we are poised in this coming year to expand our clinical footprint in HBV with the initiation of clinical trials for two...

Strategic priorities focus on late-stage development of its CRISPR-based medicines while continuing to expand and validate its industry-leading genome editing platform Submit IND application in mid-2023 as part of a global pivotal study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy; study initiation anticipated by year-end 2023 Submit IND application for NTLA-2002 for the treatment of hereditary angioedema (HAE) and initiate global Phase 2 study in 1H 2023 Present additional clinical data in 2023 from both ongoing NTLA-2001 and NTLA-2002 first-in-human studies Progress first CRISPR-based gene insertion investigational therapy in humans; submit IND or equivalent filing for NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD) in 2H 2023 Ended 2022 in a strong financial position with...

CENTREVILLE, Va., Jan. 05, 2023 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced today that the company’s BlackHorse Solutions subsidiary won a $12 million contract from the Defense Advanced Research Projects Agency (DARPA) for a research project under the Signature Management using Operational Knowledge and Environments (SMOKE) program. The cost-plus-fixed-fee contract represents new work for the company and was secured through a competitive acquisition process. As cyber networks are under persistent threat from malicious cyber actors, Parsons will develop data-driven tools to automate the planning and execution of threat-emulated cyber infrastructure needed for network security assessments under the SMOKE program. “Our offensive and defensive cyberspace operations combine leading edge technical innovations, mission...

Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis On Track to Initiate Phase 2 Proof-of-Concept Trial for NX-13 in the Second Quarter of 2023 and Report Topline Data by the Fourth Quarter of 2024 Broader, Novel Pipeline Poised for Partnering and Continued Development in the Future; Significant Optionality for Omilancor, LABP-104 and Four Promising Pre-Clinical Programs Secures Additional $16.7 Million Investment Disciplined Financial Approach Expected to Maintain Cash Runway into First Half of 2025 Company to Host Investor Call at 8:00 AM ET NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a comprehensive update on...